

**5th
ed**

**Practical Diagnosis of
Hematologic Disorders**

**Vol 2
Malignant Disorders**

Authors

Carl R Kjeldsberg, MD

Professor of Pathology, University of Utah Health Sciences Center
Chairman of the Board, ARUP Laboratories, Inc

Sherrie L Perkins, MD, PhD

Professor of Pathology, University of Utah Health Sciences Center
Chief Medical Officer, Director of Laboratories, Medical Director of Hematopathology, ARUP Laboratories, Inc

John Anastasi, MD

Associate Professor, Associate Director Hematopathology
Department of Pathology
University of Chicago Medical Center

Daniel A Arber, MD

Professor and Associate Chair of Pathology for Clinical Services
Stanford University

David W Bahler, MD, PhD

Associate Professor of Pathology, University of Utah
Director, Hematologic Flow Cytometry Laboratory, ARUP Laboratories, Inc

Robert C Blaylock, MD

Professor of Pathology, Medical Director of University Hospital Transfusion Services and ARUP Blood Services
Medical Director of the Immunohematology Reference Laboratory, ARUP Laboratories, Inc
Co-Director of University Hospital Clinical Laboratories

Kojo S J Elenitoba-Johnson, MD

Professor of Pathology, Director of Division of Translational Research
Director of Molecular Diagnostics Laboratory
Director, Molecular Genetic Pathology Program
University of Michigan

Kathryn Foucar, MD

Professor of Pathology, Vice Chair for Clinical Affairs
University of New Mexico Health Sciences Center and TriCore Reference Laboratories

Amy Heerema-McKenney, MD

Clinical Assistant Professor, Department of Pathology
Stanford University

Megan S Lim, MD, PhD

Associate Professor of Pathology, Director of Hematopathology
Director, Hematopathology Fellowship Training Program
University of Michigan

Robert W McKenna, MD

Professor and Vice Chair for Academic Affairs
Senior Consultant in Hematopathology, Department of Laboratory Medicine and Pathology
Richard D Brunning Professor of Laboratory Medicine and Pathology
University of Minnesota

LoAnn C Peterson, MD

Paul E Steiner Research Professor of Pathology, Feinberg Medical School
Northwestern University, Northwestern Memorial Hospital

George M Rodgers, MD, PhD

Professor of Medicine and Pathology, University of Utah Health Sciences Center
Medical Director, Coagulation Laboratory, ARUP Laboratories, Inc

Mohamed E Salama, MD

Assistant Professor of Pathology, University of Utah Health Sciences Center
Assistant Medical Director, Hematopathology, ARUP Laboratories, Inc

James W Vardiman, MD

Professor of Pathology
University of Chicago Medical Center

Practical Diagnosis of Hematologic Disorders

5th Edition

Vol 2
Malignant Disorders

Carl R Kjeldsberg, MD
Sherrie L Perkins, MD, PhD
Editors
et xiii alia

ASCP Press
American Society for Clinical Pathology
Chicago, IL



Publishing Team

Erik Tanck (production/designer)
Joshua Weikersheimer (publishing direction)

Notice

Trade names and equipment and supplies described herein are included as suggestions only. In no way does their inclusion constitute an endorsement or preferences by the American Society for Clinical Pathology. The ASCP did not test the equipment, supplies, or procedures and, therefore, urges all readers to read and follow all manufacturers' instructions and package insert warnings concerning the proper and safe use of products.



Copyright © 2010 by the American Society for Clinical Pathology.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Printed in Singapore

14 13 12 11 10

Vol 2 Malignant Disorders

Preface xiii

Acknowledgments xiv

Part IX Myeloid Neoplasms

MYELOPROLIFERATIVE NEOPLASMS

35. Chronic Myelogenous Leukemia, *BCR-ABL1+* 419

John Anastasi, MD
James Vardiman, MD

36. Chronic Neutrophilic Leukemia 443

John Anastasi, MD
James Vardiman, MD

37. Polycythemia Vera 449

John Anastasi, MD
James Vardiman, MD

38. Primary Myelofibrosis 467

John Anastasi, MD
James Vardiman, MD

39. Essential Thrombocythemia 487

John Anastasi, MD
James Vardiman, MD

40. Chronic Eosinophilic Leukemia, NOS 501

Sherrie Perkins, MD, PhD
Mohamed Salama, MD
James Vardiman, MD

41. Mastocytosis 509

Megan S Lim, MD, PhD

42. Myeloproliferative Neoplasms, Unclassifiable 521

James Vardiman, MD
John Anastasi, MD

**MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND ABNORMALITIES OF
PDGFRA, *PDGFRB* OR *FGFR1***

**43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities
of *PDGFRA*, *PDGFRB* or *FGFR1***

Mohamed Salama, MD
Sherrie Perkins, MD, PhD

44. Myelodysplastic/Myeloproliferative Neoplasms 535

Sherrie Perkins, MD, PhD
James Vardiman, MD

MYELODYSPLASTIC SYNDROMES

45. Myelodysplastic Syndromes 547

Sherrie L Perkins, MD, PhD
Robert W McKenna, MD

Part X Acute Myeloid Leukemias

ACUTE MYELOID LEUKEMIA AND RELATED PRECURSOR NEOPLASMS

46. Acute Myeloid Leukemia With Recurrent Genetic Abnormalities 585

Amy Heerema-McKenney, MD
Daniel A. Arber, MD

**47. Acute Myeloid Leukemia With Myelodysplasia-Related Changes
and Therapy-Related Myeloid Neoplasms 615**

Amy Heerema-McKenney, MD
Daniel A Arber, MD

48. Acute Myeloid Leukemia, NOS 621

Amy Heerema-McKenney, MD
Daniel A Arber, MD

49. Myeloid Sarcoma 633

Amy Heerema-McKenney, MD
Daniel A Arber, MD

50. Myeloid Proliferations Related to Down Syndrome 639

Amy Heerema-McKenney, MD
Daniel A Arber, MD

51. Blastic Plasmacytoid Dendritic Cell Neoplasm 645

Amy Heerema-McKenney, MD
Daniel A Arber, MD

52. Acute Leukemias of Ambiguous Lineage 653

Amy Heerema-McKenney, MD
Daniel A Arber, MD

Part XI Lymphoid Neoplasms

53. Introduction to Non-Hodgkin Lymphoma 661

Kojo SJ Elenitoba-Johnson, MD
Megan S Lim, MD, PhD
Carl Kjeldsberg, MD

Part XII Precursor Lymphoid Neoplasms

54. Precursor Lymphoid Neoplasms 691

Sherrie L Perkins MD, PhD
Robert McKenna, MD

Part XIII Mature B-Cell, T-Cell and Histiocytic Neoplasms

MATURE B-CELL NEOPLASMS**55. Mature B-Cell Neoplasms With Leukemic Manifestations 723**

LoAnn Peterson, MD

**56. Mature B-Cell Neoplasms With
Plasma Cell or Plasmacytoid Differentiation 747**

LoAnn Peterson, MD

57. Mature B-Cell Neoplasms With Primary Tissue Manifestations 769

Kojo S J Elenitoba-Johnson, MD
Megan S Lim, MD
Carl Kjeldsberg, MD

MATURE T-CELL AND NK-CELL NEOPLASMS**58. Mature T-Cell and NK-Cell Neoplasms 805**

Kojo S J Elenitoba-Johnson, MD
Megan S Lim, MD
Carl Kjeldsberg, MD

HODGKIN LYMPHOMA

59. Hodgkin Lymphoma 835

Carl Kjeldsberg, MD

Kojo S J Elenitoba-Johnson, MD

HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS

60. Histiocytic and Dendritic Cell Neoplasms 853

Megan S Lim, MD, PhD

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

61. Post-Transplant Lymphoproliferative Disorders 865

Megan S Lim, MD, PhD

Part XIV Special Techniques

62. Molecular Techniques in the Diagnosis of Hematologic Malignancies 879

Kojo S J Elenitoba-Johnson, MD

63. Flow Cytometric Analysis 899

David Bahler, MD, PhD

Appendix

Appendix: Hematology Reference Values 919

Index p index 2.1 and following

List of Tables

Ch 35. Chronic Myelogenous Leukemia, <i>BCR-ABL1+</i>	
t35.1 Features of Chronic Myelogenous Leukemia <i>BCR-ABL1+</i> , Chronic Phase	424
t35.2 WHO Criteria for Chronic Myelogenous Leukemia, Accelerated Phase	428
t35.3 CML, Blast Phase	428
t35.4 Distinguishing Features Among the Chronic Myeloid Leukemias	436
t35.5 Summary of Features of Chronic Neutrophilic Leukemia (CNL)	437
Ch 37. Polycythemia Vera	
t37.1 Stages and Associated Features in Polycythemia Vera	449
t37.2 Classification of Polycythemia	452
t37.3 WHO Recommended Criteria for the Diagnosis of Polycythemia Vera	456
t37.4 Comparison of Findings in Polycythemia Vera and Secondary Erythrocytosis	457
Ch 38. Primary Myelofibrosis	
t38.1 Causes of Bone Marrow Fibrosis	468
t38.2 Major Clinical and Laboratory Features in PMF	470
t38.3 WHO Diagnostic Criteria for Primary Myelofibrosis	471
t38.4 Myeloid Disorders With Myelofibrosis	482
t38.5 Comparison of Usual Findings in Polycythemia Vera-Polycythemic Phase, PMF-Prefibrotic Stage, and Essential Thrombocythemia	482
Ch 39. Essential Thrombocythemia	
t39.1 Causes of Marked Thrombocytosis	487
t39.2 Features Helpful in Distinguishing Essential Thrombocythemia and Secondary Thrombocytosis	489
t39.3 Revised WHO (2008) Diagnostic Criteria for the Diagnosis of Essential Thrombocythemia	490
t39.4 Morphologic Features of ET	491
t39.5 Comparison of Features of Essential Thrombocythemia With Other Chronic Myeloproliferative Disorders	495
Ch 40. Chronic Eosinophilic Leukemia, NOS	
t40.1 Diagnostic Criteria of Chronic Eosinophilic Leukemia, NOS	502
t40.2 Systemic Involvement by Chronic Eosinophilic Leukemia, NOS	503
t40.3 Differential Diagnostic Consideration for Persistent Eosinophilia	506
Ch 41. Mastocytosis	
t41.1 Classification of Mast Cell Disease (Adapted From World Health Organization Criteria)	510
t41.2 Major and Minor Diagnostic Criteria for Systemic Mastocytosis	514
t41.3 Comparison of Immunophenotypes of Mast Cells and Closely Related Cell Types	519
Ch 42. Myeloproliferative Neoplasms, Unclassifiable	
t42.1 Situations in Which a Diagnosis of Myeloproliferative Neoplasm-Unclassifiable Can Be Considered	522
Ch 43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities of <i>PDGFRB</i>, <i>PDGFRB</i> or <i>FGFR1</i>	
t43.1 Fusion Partners of <i>PDGFRB</i> and Related Cytogenetic Defects Occurring in Myeloid Neoplasms Presenting With Eosinophilia	530
t43.2 <i>FGFR1</i> Gene Fusion Partners	533

Ch 44. Myelodysplastic/Myeloproliferative Neoplasms	
t44.1 Features Distinguishing Myelodysplastic Syndrome (MDS) from Myeloproliferative Neoplasms (MPN)	535
t44.2 WHO Classification of Myelodysplastic/Myeloproliferative Neoplasms	535
t44.3 Diagnostic Criteria for Chronic Myelomonocytic Leukemia	536
t44.4 Diagnostic Criteria for Atypical Chronic Myeloid Leukemia, <i>BCR-ABL1</i> — (aCML)	540
t44.5 Comparison of Chronic Myelogenous Leukemia (CML) and Atypical Chronic Myelogenous Leukemia (aCML)	541
t44.6 Diagnostic Criteria of Juvenile Myelomonocytic Leukemia	543
t44.7 Diagnostic Criteria for Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U)	545
Ch 45. Myelodysplastic Syndromes	
t45.1 International Prognostic Scoring System (IPSS) Thresholds for Cytopenias in the Diagnosis of Myelodysplastic Syndromes	548
t45.2 WHO Classification of MDS	549
t45.3 Hematologic Findings in Myelodysplastic Syndromes	549
t45.4 Morphologic Abnormalities in Myelodysplastic Syndromes	551
t45.5 Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes	559
t45.6 International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes	561
t45.7 Chromosome Abnormalities Seen in MDS and Candidate Genes Affected	561
t45.8 Immunophenotypic Abnormalities Observed in Myelodysplastic Syndromes	562
t45.9 Peripheral Blood and Bone Marrow Findings in Myelodysplastic Syndromes	564
t45.10 Refractory Anemia (RA)	566
t45.11 Refractory Anemia With Ringed Sideroblasts (RARS)	569
t45.12 Refractory Cytopenia With Multilineage Dysplasia (RCMD)	570
t45.13 Refractory Anemia With Excess Blasts (RAEB)	572
t45.14 Myelodysplastic Syndrome With Isolated del(5q)	573
t45.15 Pediatric MDS	574
t45.16 WHO Minimal Diagnostic Criteria for Refractory Cytopenia of Childhood	575
t45.17 Comparison of Morphological Criteria of Hypoplastic Refractory Cytopenia of Childhood and Aplastic Anemia	576
t45.18 Differential Diagnostic Considerations in Myelodysplastic Syndromes	577
t45.19 Survival, Prognosis and Evolution to AML in Adult Patients with MDS	579
t45.20 Indicators of Good and Poor Prognosis in Myelodysplastic Syndromes	580
Ch 46. Acute Myeloid Leukemia (AML) With Recurrent Genetic Abnormalities	
t46.1 French-American-British (FAB) Classification Morphologic Categories of AML	586
t46.2 WHO 2008 Classification of Acute Myeloid Leukemia	586
t46.3 Cytologic Features of Blasts in Acute Myeloid and Acute Lymphoblastic Leukemias	587
t46.4 Cytochemical Stains and Their Utility	588
t46.5 Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research Composite Prognostic Index for Adult AML (age <60)	590
t46.6 Common Variant Translocations of APL	600
t46.7 Common <i>MLL</i> Fusion Transcripts in AML	602
Ch 47. AML With Myelodysplasia-Related Changes and Therapy-Related Myeloid Neoplasms	
t47.1 Criteria for Diagnosis of AML With Myelodysplasia-Related Changes	616
Ch 48. AML, NOS	
t48.1 Differential Diagnosis of Acute Basophilic Leukemia (ABL)	630
Ch 49. Myeloid Sarcoma	
t49.1 Characteristics of Adult vs Pediatric Myeloid Sarcoma	635

Ch 51. Blastic Plasmacytoid Dendritic Cell Neoplasm	
t51.1 Immunophenotypic Overlap Between Blastic Plasmacytoid Dendritic Cell Neoplasm and Cases of Cutaneous Involvement by Acute Myeloid Leukemia	650
t51.2 Distinguishing Blastic Plasmacytoid Dendritic Cell Neoplasm From CD56+ True NK-Cell, NK/T-Cell and γ/δ T-Cell Lymphoma/Leukemias	651
Ch 53. Introduction to Non-Hodgkin Lymphoma	
t53.1 Cytogenetic and Molecular Abnormalities in Non-Hodgkin Lymphoma	662
t53.2 Predisposing Conditions and Factors in the Development of Non-Hodgkin Lymphoma	663
t53.3 Comparison of Non-Hodgkin and Hodgkin Lymphomas	664
t53.4 Stages of Lymphoma	664
t53.5 National Cancer Institute Modified Staging for Intermediate- and High-Grade Lymphomas	664
t53.6 Staging Procedures for Non-Hodgkin Lymphoma	665
t53.7 Principles of Classification of Non-Hodgkin Lymphoma	666
t53.8 Mature Neoplasms	667
t53.9 Major Antibodies Used in Immunophenotyping of Malignant Lymphomas in Paraffin Sections	677-678
t53.10 Application of Immunophenotypic Analysis	679
t53.11 Undifferentiated Large Neoplasm Antibody Panel for Paraffin Sections	679
t53.12 Immunophenotyping of Non-Hodgkin and Hodgkin Lymphomas in Paraffin Sections	679
t53.13 Comparison of Non-Hodgkin Lymphoma Features in Children and Adults	681
t53.14 Classification of Non-Hodgkin Lymphoma in Children	681
t53.15 Comparison of Morphologic and Immunophenotypic Features in Childhood Non-Hodgkin Lymphomas	682
t53.16 Causes of Lymph Node Enlargement Simulating Malignant Lymphoma	682
t53.17 International Prognostic Index of Parameters and Relative Risk	683
t53.18 International Prognostic Index: The International Index and Age-Adjusted Index	683
t53.19 Histopathology and Prognosis in Non-Hodgkin Lymphomas	684
t53.20 Cellular Prognostic in Non-Hodgkin Lymphomas	684
t53.21 Checklist for the Reporting of Lymphoid Neoplasms	685
t53.22 New Therapeutic Agents in Malignant Lymphoma	687
Ch 54. Precursor Lymphoid Neoplasms	
t54.1 WHO Classification of Acute Lymphoblastic Leukemia/Lymphoma	692
t54.2 Frequency of Clinical and Laboratory Findings at Diagnosis in Children and Adults with ALL	693
t54.3 Characteristic Clinical Features of Precursor T-ALL	693
t54.4 Distribution of White Cell Counts at Diagnosis	694
t54.5 FAB Morphologic Classification of Lymphoblasts	696
t54.6 Common Antigen Expression Patterns of Acute Lymphoblastic Leukemias/ Lymphoblastic Lymphomas	703
t54.7 Distribution of Immunophenotypic Subtypes in Acute Lymphoblastic Leukemia	703
t54.8 Correlation of Prognosis with Bone Marrow Cytogenetic Findings in ALL	707
t54.9 Cytogenetic Translocations Associated With Specific Molecular Genetic Abnormalities in ALL	711
t54.10 Most Significant Prognostic Indicators in Pediatric ALL	717
t54.11 Adverse Prognostic Factors in Adult and Pediatric ALL	717
Ch 55. Mature B-Cell Neoplasms With Leukemic Manifestations	
t55.1 Mature B-Cell Neoplasms With Leukemic Manifestations	723
t55.2 Rai Clinical Staging System for Chronic Lymphocytic Leukemia	724
t55.3 Binet Staging System for Chronic Lymphocytic Leukemia	724
t55.4 Typical Phenotypes of B-Cell Chronic Lymphoid Leukemias and Lymphomas	730

Ch 56. Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation	
t56.1 Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation	747
t56.2 Monoclonal Immunoglobulins in Mature B-Cell Neoplasms With Plasma Cell Differentiation	748
t56.3 Approximate Incidence of Monoclonal Gammopathies in the United States	749
t56.4 Diagnostic Criteria for Monoclonal Gammopathy of Undetermined Significance	749
t56.5 Course of 241 Patients With Monoclonal Gammopathy of Undetermined Significance	750
t56.6 Diagnostic Criteria for Plasma Cell Myeloma	751
Ch 57. Mature B-Cell Neoplasms With Primary Tissue Manifestations	
t57.1 Mature B-Cell Neoplasms With Primary Tissue Manifestations	769
t57.2 Small Lymphocytic B-Cell Neoplasms: Characteristic Morphologic Features	770
t57.3 Small Lymphocytic B-Cell Neoplasms: Immunophenotypic Features	770
t57.4 Useful Features in the Differential Diagnosis of Mediastinal Lymphomas	794
Ch 58. Mature T-Cell and NK-Cell Neoplasms	
t58.1 Mature T-Cell and NK-Cell Neoplasms	805
t58.2 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers With Frequent Leukemic Presentation	810
t58.3 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers With Frequent Cutaneous Involvement	825
t58.4 Differential Diagnosis of Nodal Peripheral T-Cell Lymphoma, Not Otherwise Specified	827
t58.5 Characteristics of Variant <i>ALK</i> Translocations	832
Ch 59. Hodgkin Lymphoma	
t59.1 Staging Procedures in Hodgkin Lymphoma	837
t59.2 The Cotswald Modification of the Ann Arbor Staging Classification for Hodgkin Lymphoma	837
t59.3 World Health Organization (WHO) Classification of Hodgkin Lymphoma	837
t59.4 Immunophenotype Features of RS Cells and L&H Cells	839
t59.5 Differential Diagnosis of Hodgkin Lymphoma	839
t59.6 Immunophenotypic Distinction of Hodgkin Lymphoma From Non-Hodgkin Lymphoma	851
Ch 60. Histiocytic and Dendritic Cell Neoplasms	
t60.1 Immunophenotypic Features Useful in the Distinction of Macrophages, Langerhans Cells, Dendritic Cells and Lymphocytes	854
t60.2 Clinical Variants of Langerhans Cell Histiocytosis	856
t60.3 Differential Diagnosis of Langerhans Cell Histiocytosis	860
Ch 61. Post-Transplant Lymphoproliferative Disorders	
t61.1 Comparison of Post-Transplant Lymphoproliferative Disorders Occurring in Solid Organ and Bone Marrow Transplant Patients	866
t61.2 Evaluation for Diagnosis of PTLDs	867
t61.3 General Categories of Post-Transplantation Lymphoproliferative Disorders	868
Ch 62. Molecular Techniques in the Diagnosis of Hematologic Malignancies	
t62.1 Comparison of Molecular Methods Used in Diagnostic Hematopathology	880
t62.2 Genetic Alterations in Hematologic Malignancies	881-882
Ch 63. Flow Cytometric Analysis	
t63.1 Fluorochromes Often Used With 488-nm Wavelength Excitation	900
t63.2 Common Hematopoietic Cell Antigens Evaluated With Flow Immunophenotyping	903
t63.3 Common Antigens Used to Assess Acute Leukemia Blast Lineage by Flow Cytometry	907
t63.4 Characteristic Phenotypic Features Associated with Specific Acute Leukemias	907
t63.5 Typical Immunophenotypes of Mature B-Cell Neoplasms	910
t63.6 Phenotypic Features Associated With Specific Mature T-Cell Neoplasms	913

Preface

The goal of this book, beginning with the first edition in 1989, has been to provide an up-to-date, concise source of guidelines to the selection, use and interpretation of laboratory tests, while at the same time providing an overview of the pathogenesis and clinical features of the most common hematologic disorders.

Though the size and scope of this book have increased considerably, keeping pace with the expansion of the knowledge and diagnostic complexity in hematopathology, the focus on providing practical information has not changed. Each chapter follows a practical format to make finding specific information easy. This fifth edition contains substantial new information, particularly with regard to molecular modalities and utilization of ancillary testing in the diagnosis of hematologic disorders. The new edition uses the framework of the 2008 WHO classification for malignancies, and provides up-to-date diagnostic approaches, correct usage of laboratory testing, and algorithms for diagnosis of both benign and malignant disorders.

We hope that this newest edition will be an even more valuable tool and resource for a broad audience, including pathologists, residents and fellows in pathology and medicine, hematologists/oncologists, internists, pediatricians, medical students and medical technologists, as well as for those preparing for board examinations in pathology and internal medicine.

We welcome your comments or suggestions for future editions and trust that this book will provide the quality information and education you've come to expect.

Acknowledgements

We wish to express our appreciation to Joshua Weikersheimer of the ASCP Press, for his assistance in all aspects of publication, and to Susan Flinders for administrative assistance.

We want to also thank our colleagues in the Department of Pathology at the University of Utah, and the staff at ARUP Laboratories for their support. Present and former hematopathology fellows have provided much inspiration

Most of all, we are grateful for the support and love from our families, Gillean, Tanya, Kristina, Don, Rachel and Jessica.